Exome Asset Management LLC Buys 69,656 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Exome Asset Management LLC boosted its stake in Rezolute, Inc. (NASDAQ:RZLT) by 24.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 352,056 shares of the company’s stock after buying an additional 69,656 shares during the quarter. Exome Asset Management LLC owned approximately 0.61% of Rezolute worth $1,707,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of RZLT. Jeppson Wealth Management LLC acquired a new stake in shares of Rezolute in the 2nd quarter valued at $45,000. MML Investors Services LLC bought a new position in Rezolute during the 3rd quarter valued at about $57,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Rezolute during the third quarter worth about $65,000. Virtu Financial LLC increased its holdings in shares of Rezolute by 58.0% during the third quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock worth $126,000 after buying an additional 9,551 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Rezolute by 205.8% in the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock valued at $145,000 after acquiring an additional 22,660 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Rezolute

In related news, CFO Daron Evans bought 9,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $4.60 per share, for a total transaction of $41,400.00. Following the transaction, the chief financial officer now owns 140,900 shares of the company’s stock, valued at $648,140. This represents a 6.82 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 18.39% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on RZLT. Guggenheim initiated coverage on Rezolute in a research report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. Wedbush restated an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a research note on Monday, November 4th. BTIG Research lifted their price target on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Rezolute in a report on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a research report on Friday, September 20th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $24.13.

Rezolute Trading Down 1.1 %

Shares of NASDAQ:RZLT opened at $4.59 on Friday. Rezolute, Inc. has a 1-year low of $0.81 and a 1-year high of $6.19. The stock has a market capitalization of $265.96 million, a P/E ratio of -3.61 and a beta of 1.01. The business has a 50-day moving average price of $5.16 and a two-hundred day moving average price of $4.77.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). As a group, equities analysts predict that Rezolute, Inc. will post -0.99 EPS for the current year.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.